Clinical trials: Aetiology
Infection of Upper Respiratory Tract Caused by 2019-nCoV
SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
- Trial name
- NCT06042764
- Testing
- SA55 Injection
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Schizophrenia
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
This is an observational, non-interventional study that will include two cohorts of patients with schizophrenia who initiated maintenance treatment during a schizophrenia-related hospitalisation or during the immediate three…
- Trial name
- NCT03130465
- Where
- 67 sites in France, Germany and 2 more
- Volunteers
- 636 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudomonas aeruginosa infections, for which no…
- Trial name
- NCT03395743
- Testing
- AB-PA01
- Sponsor
- Armata Pharmaceuticals, Inc.
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
The purpose of this study is to determine whether injections with increasing doses (up to 800 units) of Botulinum toxin type A into muscles of the leg and/or arm are safe and effective in treating patients with spasticity on one…
- Trial name
- NCT01603459
- Testing
- IncobotulinumtoxinA
- Where
- 33 sites in United States, Canada and 6 more
- Volunteers
- 155 people
- Sponsor
- Merz Pharmaceuticals GmbH
Atrial Fibrillation, Atrial Flutter
Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction
- Trial name
- EmbraceAC (NCT00691470)
- Testing
- ATI-5923, Coumadin (warfarin)
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARYx Therapeutics
Chronic Pain, Diabetic Neuropathies
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing…
- Conditions
- Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
- Trial name
- NCT01939366
- Testing
- Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg
- Where
- 82 sites in United States, Austria and 6 more
- Volunteers
- 699 people
- Sponsor
- Tris Pharma, Inc.
Gram-Positive Bacterial Infections
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
This study is a retrospective, observational study to evaluate oritavancin use in participants under real world conditions.
- Trial name
- NCT03159403
- Testing
- Oritavancin
- Where
- 21 sites in United States
- Volunteers
- 325 people
- Sponsor
- Melinta Therapeutics, Inc.
Prevention of Infectious Disease Caused by SARS-CoV-2
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19
To provide more information on safety profile of VAXZEVRIA in Japanese subjects, specific drug use result study in subjects with underling disease at higher risk of worsening COVID-19 is planned as an additional pharmacovigilance…
- Trial name
- NCT05084755
- Where
- 3 sites in Japan
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
This study aims to evaluate the efficacy and safety of GB06 (a biosimilar of Norditropin®FlexProTM from Novo Nordisk) for the treatment of growth disorders caused by growth hormone deficiency (GHD) in children.
- Conditions
- Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children, Growth Hormone Deficiency, Pediatric
- Trial name
- NCT07553351
- Testing
- GB06, Norditropin®FlexProTM
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Kexing Biopharm Co., Ltd.
Respiratory Syncytial Virus Infections
A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
The purpose of the study is to learn about the safety and amount of sisunatovir in the blood of infants and children up to age 60 months.
- Trial name
- NCT06102174
- Testing
- Active
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 10 people
- Sponsor
- Pfizer
Pharyngitis, Tonsillitis
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
This Post-Authorization Safety Study (PASS) is intended to fulfill a regulatory post-marketing requirement to provide data regarding visual abilities in children taking azithromycin (immediate-release formulation) for acute…
- Trial name
- NCT01919996
- Testing
- Azithromycin
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Pfizer
Spinal Fractures
A Safety and Efficacy Study for Treatment of Painful Vertebral Compression Fractures Caused by Osteoporosis
Doctors are studying an investigational treatment to be used during the vertebroplasty procedure when treating vertebral compression fractures (spine fractures) that may help to reduce pain and restore mobility.
- Trial name
- NCT00290862
- Testing
- Percutaneous Vertebral Augmentation of compression fractures
- Where
- 18 sites in United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Orthovita d/b/a Stryker
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
- Trial name
- NCT03602261
- Testing
- Calcifediol Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 44 people
- Sponsor
- OPKO Health, Inc.
Macular Edema Secondary to Retinal Vein Occlusion
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked.
- Trial name
- QUASAR (NCT05850520)
- Testing
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Fluorescein
- Where
- 273 sites in United States, Australia and 25 more
- Volunteers
- 892 people
- Sponsor
- Bayer
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Expanded access for participants with cancer caused by an abnormal RET gene that did not respond/is no longer responding to treatment with a type of drug called a RET inhibitor.
- Trial name
- NCT05225259
- Testing
- LOXO-260
- Sponsor
- Eli Lilly and Company
Contact Lens Related Dry Eye
Clinical Evaluation of the Causes of Contact Lens Related Dry Eye
The purpose of this study was to clinically evaluate the potential causes of contact lens-related dry eye.
- Trial name
- NCT00995189
- Testing
- Opti-Free RepleniSH, ReNu MultiPlus, Contact lenses
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Alcon Research
SARS-CoV-2 Infection, COVID-19
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to…
- Trial name
- NCT05541861
- Testing
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg
- Where
- 17 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, SARS-CoV 2
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)
The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by…
- Conditions
- COVID-19, SARS-CoV 2, Respiratory Disease, Pneumonia, Viral
- Trial name
- NCT04456088
- Testing
- 150 ppm Nitric Oxide delivered through LungFit Delivery System, 80 ppm Nitric Oxide delivered through LungFit Delivery System
- Sponsor
- Beyond Air Inc.
Clostridium; Difficile, As Cause of Disease Classified Elsewhere, Clostridium Difficile Diarrhea
Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea
This is a single center, randomized, exploratory clinical investigation that will evaluate the safety and efficacy of Toxclean (ABResearch srl) as add on treatment to Standard therapy in 24 patients with recurrent CDAD.
- Trial name
- NCT06839209
- Testing
- Toxclean 1g
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- ABResearch S.r.l.
Liver Cirrhoses
Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
The study aims to evaluate the effect of allogeneic mesenchymal stem cell therapy on patients who suffered from liver cirrhosis caused by Hepatitis B.
- Trial name
- NCT04357600
- Testing
- Allogeneic Umbilical Cord Mesenchymal Stem Cell
- Where
- Indonesia
- Volunteers
- 12 people
- Sponsor
- PT. Prodia Stem Cell Indonesia